102 related articles for article (PubMed ID: 30039745)
41. Diagnosis and prognosis of Alzheimer's disease using brain morphometry and white matter connectomes.
Wang Y; Xu C; Park JH; Lee S; Stern Y; Yoo S; Kim JH; Kim HS; Cha J;
Neuroimage Clin; 2019; 23():101859. PubMed ID: 31150957
[TBL] [Abstract][Full Text] [Related]
42. A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data.
Li H; Habes M; Wolk DA; Fan Y;
Alzheimers Dement; 2019 Aug; 15(8):1059-1070. PubMed ID: 31201098
[TBL] [Abstract][Full Text] [Related]
43. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease.
van Duijn CM; Havekes LM; Van Broeckhoven C; de Knijff P; Hofman A
BMJ; 1995 Mar; 310(6980):627-31. PubMed ID: 7703749
[TBL] [Abstract][Full Text] [Related]
44. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z;
Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129
[TBL] [Abstract][Full Text] [Related]
45. Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment.
Suppa P; Hampel H; Kepp T; Lange C; Spies L; Fiebach JB; Dubois B; Buchert R;
J Alzheimers Dis; 2016; 51(3):867-73. PubMed ID: 26923010
[TBL] [Abstract][Full Text] [Related]
46. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
Jones RW; McCrone P; Guilhaume C
Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
[TBL] [Abstract][Full Text] [Related]
47. Analysis of longitudinal diffusion-weighted images in healthy and pathological aging: An ADNI study.
Kruggel F; Masaki F; Solodkin A;
J Neurosci Methods; 2017 Feb; 278():101-115. PubMed ID: 28057473
[TBL] [Abstract][Full Text] [Related]
48. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
49. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
50. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.
Scarabino D; Broggio E; Gambina G; Maida C; Gaudio MR; Corbo RM
Am J Med Genet B Neuropsychiatr Genet; 2016 Dec; 171(8):1131-1138. PubMed ID: 27604972
[TBL] [Abstract][Full Text] [Related]
51. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
[TBL] [Abstract][Full Text] [Related]
52. Standardization of hippocampus volumetry using automated brain structure volumetry tool for an initial Alzheimer's disease imaging biomarker.
Abrigo J; Shi L; Luo Y; Chen Q; Chu WCW; Mok VCT;
Acta Radiol; 2019 Jun; 60(6):769-776. PubMed ID: 30185071
[TBL] [Abstract][Full Text] [Related]
53. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
Hamelin L; Lagarde J; Dorothée G; Potier MC; Corlier F; Kuhnast B; Caillé F; Dubois B; Fillon L; Chupin M; Bottlaender M; Sarazin M
Brain; 2018 Jun; 141(6):1855-1870. PubMed ID: 29608645
[TBL] [Abstract][Full Text] [Related]
54. Apolipoprotein E and Alzheimer's disease: a genetic, molecular and neuroimaging review.
Swartz RH; Black SE; St George-Hyslop P
Can J Neurol Sci; 1999 May; 26(2):77-88. PubMed ID: 10352866
[TBL] [Abstract][Full Text] [Related]
55. Multivariate Prediction of Hippocampal Atrophy in Alzheimer's Disease.
Liedes H; Lötjönen J; Kortelainen JM; Novak G; van Gils M; Gordon MF; ;
J Alzheimers Dis; 2019; 68(4):1453-1468. PubMed ID: 30909211
[TBL] [Abstract][Full Text] [Related]
56. A novel method and software for automatically classifying Alzheimer's disease patients by magnetic resonance imaging analysis.
Previtali F; Bertolazzi P; Felici G; Weitschek E
Comput Methods Programs Biomed; 2017 May; 143():89-95. PubMed ID: 28391822
[TBL] [Abstract][Full Text] [Related]
57. Herpes simplex virus type 1, apolipoprotein E and Alzheimer' disease.
Itzhaki R
Herpes; 2004 Jun; 11 Suppl 2():77A-82A. PubMed ID: 15319093
[TBL] [Abstract][Full Text] [Related]
58. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Pina MA
Am J Psychiatry; 2005 Apr; 162(4):667-75. PubMed ID: 15800137
[TBL] [Abstract][Full Text] [Related]
59. Stochastic model of Alzheimer's disease progression using two-state Markov chains.
Parks ME
PLoS One; 2024; 19(1):e0295578. PubMed ID: 38241349
[TBL] [Abstract][Full Text] [Related]
60. Non-homogeneous Markov process models with informative observations with an application to Alzheimer's disease.
Chen B; Zhou XH
Biom J; 2011 May; 53(3):444-63. PubMed ID: 21491475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
